The placebo response in functional bowel disorders: Perspectives and putative mechanisms

Neurogastroenterology and Motility

Volumn 17, Issue 3, 2005, Pages 325-331

  Enck, Paul ^a   Klosterhalfen, S ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Clinics of Vascular Surgery   (Germany)

Author keywords

Clinical trials; Functional bowel disorders; Placebo response

Indexed keywords

ANTIDEPRESSANT AGENT; BULKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PEPPERMINT OIL; PLACEBO; PROKINETIC AGENT; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN FUNCTION; CONDITIONING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; ENTERITIS; FUNCTIONAL DISEASE; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL DETECTION;

GASTROINTESTINAL DISEASES; HUMANS; PLACEBO EFFECT; RESEARCH DESIGN;

EID: 20044378862     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2005.00676.x     Document Type: Review

References (46)

1. Welge JA, Keck PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl) 2003; 166: 1-10.
2. Robertson C, Idris NR, Boyle P. Beyond classical meta-analysis: can inadequately reported studies be included? Drug Discov Today 2004; 9: 924-31.
3. Moayyedi P. Meta-analysis: can we mix apples with oranges? Am J Gastroenterol 99; 2004: 2297-301.
4. Mearin F, Balboa A, Zarate N, Cucala M, Malagelada JR. Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999; 94: 116-25.
5. Allescher HD, Bockenhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-41.
6. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle elaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61.
7. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86.
8. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
9. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-74.
10. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-41.
11. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107: 91S-97S.
12. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 1854-8.
13. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo response rates of remission and response in clinical trials of active Grohn's disease. Gastroenterology 2004; 126: 1257-69.
14. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002; 136: 471-6.
15. de Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen JG, Kleijnen J. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999; 48: 853-60.
16. Weihrauch TR, Gauler TC. Placebo - efficacy and adverse effects in controlled clinical trials. Arzneimittelforschung 1999; 49: 385-93.
17. Moerman DE. Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure. Med Anthropol Q 2000; 14: 51-72.
18. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004; Issue 1. Art No. CD003012.pub2. DOI:10.1002/14651858.CD003012.pub2.
19. Enserink M. Can the placebo be the cure? Science 1999; 284: 238-40.
20. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prev Treat 1998; 12: http://journals.apa.org/prevention/volume1/pre0010002a.html (posted: 26 June 1998).
21. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression - variable, substantial, and growing. JAMA 2002; 287: 1840-7.
22. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-602.
23. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004; 256: 91-100.
24. Vase L, Riley JL 3rd, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002; 99: 443-52.
25. Andrews G. Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry 2001; 178: 192-4.
26. Welge JA, Keck PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl) 2003; 166: 1-10.
27. Evans KR, Sills T, Wunderlich GR, McDonald HP. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? J Psychiatr Res 2004; 38: 437-44.
28. Aulas JJ, Rosner I. Efficacy of a non-blind placebo prescription. Encephale 2003; 29: 68-71.
29. Klosterhalfen S, Rüttgers A, Krumrey E et al. Pavlovian conditioning of taste aversion using a motion sickness paradigm. Psychosom Med 2000; 62: 671-7.
30. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003; 23: 4315-23.
31. ter Riet G, de Craen AJ, de Boer A, Kessels AG. Is placebo analgesia mediated by endogenous opioids? A systematic review. Pain 1998; 76: 273-5.
32. Grevert P, Albert LH, Goldstein A. Partial antagonism of placebo analgesia by naloxon. Pain 1983; 16: 129-43.
33. Gracley RH, Dubner R, Wolskee PJ, Deeter WR. Placebo and naloxon can alter postsurgical pain by separate mechanisms. Nature 1983; 306: 264-5.
34. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997; 71: 135-40.
35. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003; 105: 17-25.
36. Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003; 105: 223-30.
37. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002; 295: 1737-40.
38. Wager TD, Rittling JK, Smith EE et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 2004; 303: 1162-7.
39. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-6.
40. Benedetti F, Colloca L, Torre E et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neurosci 2004; 7: 587-8.
41. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159: 122-9.
42. Mayberg HS, Silva JA, Brannan SK et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-37.
43. Lieberman MD, Jarcho JM, Berman S et al. The neural correlates of placebo efects: a disruption account. NeuroImage 2004; 22: 447-55.
44. Berman SM, Chang L, Suyenobu B et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 2002; 123: 969-77.
45. Wood JN, Grafman J. Human prefrontal cortex: processing and representational perspectives. Nat Rev Neurosci 2003; 4: 139-47.
46. Chey WD, Chey WY, Heath AT et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2185-203.